In a recent development, the Food and Drug Administration has given emergency use authorization to Novavax’s updated protein-based Covid vaccine for individuals aged 12 and above. This approval opens up the competition for Novavax’s shot against the well-established Pfizer and Moderna vaccines during the upcoming fall and winter seasons.
Novavax’s vaccine specifically targets the omicron subvariant JN.1, which has been prevalent in the United States in recent months. Although accounting for only 0.2% of cases nationally, this variant raises concerns due to its contagious nature. The company assures that its vaccine offers protection against related variants like KP.2.3, KP.3, KP.3.1.1, and LB.1, which are currently dominant in the country. Novavax plans to make its shot widely available at various locations across the U.S., including retail pharmacies, independent pharmacies, and regional grocery stores.
Following the FDA’s announcement, Novavax’s shares surged by more than 8% on Friday. This approval comes shortly after the regulatory body authorized updated messenger RNA vaccines from Pfizer and Moderna, targeting a different offshoot of JN.1 known as KP.2. The timeline of FDA approvals in the past has put Novavax at a disadvantage compared to its competitors. However, public health officials view Novavax’s vaccine as a valuable alternative for individuals hesitant to receive mRNA shots from Pfizer and Moderna, as Novavax’s technology is based on protein, a traditional approach used in various routine vaccinations.
As the fall and winter approach, it remains uncertain how many people will opt for a new Covid vaccine. Currently, only about 22.5% of the U.S. population is fully vaccinated. The availability of Novavax’s vaccine provides individuals with an additional choice in protecting themselves against the virus.
The authorization of Novavax’s Covid vaccine by the FDA marks a significant step in expanding vaccination options for the public. With its unique protein-based technology and broad distribution plans, Novavax aims to contribute to the ongoing efforts in combating the spread of Covid-19. As the vaccination landscape evolves, individuals have the opportunity to make informed choices regarding their health and well-being.